Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-blind Study of Siltuximab (Anti-IL-6 Monoclonal Antibody) or Placebo in Combination With VELCADE and Dexamethasone for the Treatment of Subjects With Relapsed or Refractory Multiple Myeloma.

Trial Profile

A Phase 3, Randomized, Double-blind Study of Siltuximab (Anti-IL-6 Monoclonal Antibody) or Placebo in Combination With VELCADE and Dexamethasone for the Treatment of Subjects With Relapsed or Refractory Multiple Myeloma.

Status: Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 05 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Siltuximab (Primary) ; Bortezomib; Dexamethasone
  • Indications Multiple myeloma
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Sponsors Centocor; Janssen Biotech

Most Recent Events

  • 05 Oct 2021 This trial has been completed in Spain, according to European Clinical Trials Database. (2011-09-08)
  • 02 Feb 2020 This trial has been discontinued in Netherlands as per EudraCT Database
  • 11 Aug 2012 Additional trial location (Germany) added as reported by European Clinical Trials Database.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top